TIMP-1 Promotes Accumulation of Cancer Associated Fibroblasts and Cancer Progression

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Oct 22

PMID 24143225

Citations 69

Authors

Yixuan Gong

Evita Scott

Rong Lu

Yin Xu

William K Oh

Qin Yu

Affiliations

Soon will be listed here.

Abstract

Treatment options for late stage prostate and colon cancer are limited and there is an urgent need to develop more effective and targeted novel therapies, which starts with identification and validation of novel therapeutic targets. Recent clinical studies have demonstrated that tissue inhibitor matrix metalloproteinase-1 (TIMP-1) levels are elevated in cancer patient plasma and elevated TIMP-1 levels are associated with worse clinical outcomes. However, it is unknown whether TIMP-1 serves merely as a biomarker of cancer progression or has a functional role in promoting cancer progression and can serve as a cancer therapeutic target, which is the main objective of this study. Here, we show that stroma of human prostate and colon cancer express higher levels of TIMP-1 compared to their normal counterparts and increased expression of TIMP-1 promotes in vivo growth of both cancer types. We demonstrate for the first time that increased TIMP-1 expression stimulates accumulation of cancer associated fibroblasts (CAFs) within prostate and colon cancer tissues and that TIMP-1 enhances prostate CAF proliferation and migration in vitro and promotes ERK1/2 kinase activation in these CAF cells. Our results establish the novel promotive effects of TIMP-1 on cancer progression and on accumulation of CAFs that in turn provides a pro-tumor microenvironment. Together, these results establish the potential of TIMP-1 as a novel target for cancer therapy and the mechanism underlying the pro-tumor activity of TIMP-1.

Citing Articles

Pan-cancer secreted proteome and skeletal muscle regulation: insight from a proteogenomic data-driven knowledge base.

Parry T, Gilmore L, Khamoui A Funct Integr Genomics. 2025; 25(1):14.

PMID: 39812750 DOI: 10.1007/s10142-024-01524-7.

The role of cancer-associated fibroblasts in the invasion and metastasis of colorectal cancer.

Yin J, Zhu W, Feng S, Yan P, Qin S Front Cell Dev Biol. 2024; 12:1375543.

PMID: 39139454 PMC: 11319178. DOI: 10.3389/fcell.2024.1375543.

Advancements in 3D In Vitro Models for Colorectal Cancer.

Vitale S, Calapa F, Colonna F, Luongo F, Biffoni M, De Maria R Adv Sci (Weinh). 2024; 11(32):e2405084.

PMID: 38962943 PMC: 11348154. DOI: 10.1002/advs.202405084.

Epigenetic and proteomic signatures associate with clonal hematopoiesis expansion rate.

Mack T, Raddatz M, Pershad Y, Nachun D, Taylor K, Guo X Nat Aging. 2024; 4(8):1043-1052.

PMID: 38834882 PMC: 11832052. DOI: 10.1038/s43587-024-00647-7.

Identification of a novel macrophage-related prognostic signature in colorectal cancer.

Lin D, Zheng T, Huang S, Liu R, Guan S, Zhang Z Sci Rep. 2024; 14(1):2767.

PMID: 38307957 PMC: 10837438. DOI: 10.1038/s41598-024-53207-9.

References

Zhang H, Wang Y, Han G, Shi Y . TIMP-3 gene transfection suppresses invasive and metastatic capacity of human hepatocarcinoma cell line HCC-7721. Hepatobiliary Pancreat Dis Int. 2007; 6(5):487-91. View

Crocker M, Ashley S, Giddings I, Petrik V, Hardcastle A, Aherne W . Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. Neuro Oncol. 2010; 13(1):99-108. PMC: 3018902. DOI: 10.1093/neuonc/noq170. View

Ross R, Galsky M, Scher H, Magidson J, Wassmann K, Lee G . A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol. 2012; 13(11):1105-13. DOI: 10.1016/S1470-2045(12)70263-2. View

Kawamata H, Kawai K, Kameyama S, Johnson M, Stetler-Stevenson W, Oyasu R . Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int J Cancer. 1995; 63(5):680-7. DOI: 10.1002/ijc.2910630513. View

Bourboulia D, Stetler-Stevenson W . Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010; 20(3):161-8. PMC: 2941566. DOI: 10.1016/j.semcancer.2010.05.002. View

Zagouri F, Sergentanis T, Kalogera E, Provatopoulou X, Chrysikos D, Zografos E . Serum MMPs and TIMPs: may be predictors of breast carcinogenesis?. Clin Chim Acta. 2010; 412(7-8):537-40. DOI: 10.1016/j.cca.2010.11.037. View

Schelter F, Grandl M, Seubert B, Schaten S, Hauser S, Gerg M . Tumor cell-derived Timp-1 is necessary for maintaining metastasis-promoting Met-signaling via inhibition of Adam-10. Clin Exp Metastasis. 2011; 28(8):793-802. DOI: 10.1007/s10585-011-9410-z. View

Fu X, Parks W, Heinecke J . Activation and silencing of matrix metalloproteinases. Semin Cell Dev Biol. 2007; 19(1):2-13. DOI: 10.1016/j.semcdb.2007.06.005. View

Kawashiri S, Tanaka A, Noguchi N, Hase T, Nakaya H, Ohara T . Significance of stromal desmoplasia and myofibroblast appearance at the invasive front in squamous cell carcinoma of the oral cavity. Head Neck. 2009; 31(10):1346-53. DOI: 10.1002/hed.21097. View

10.

Chetty C, Lakka S, Bhoopathi P, Kunigal S, Geiss R, Rao J . Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix metalloproteinase 2-down-regulated lung cancer. Cancer Res. 2008; 68(12):4736-45. PMC: 2586602. DOI: 10.1158/0008-5472.CAN-07-6612. View

11.

Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P . Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol. 2002; 197(3):307-13. DOI: 10.1002/path.1129. View

12.

Wang J, Ying G, Wang J, Jung Y, Lu J, Zhu J . Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression. Cancer Res. 2010; 70(2):471-80. PMC: 3086494. DOI: 10.1158/0008-5472.CAN-09-2863. View

13.

Osanto S, van Poppel H . Emerging novel therapies for advanced prostate cancer. Ther Adv Urol. 2012; 4(1):3-12. PMC: 3263924. DOI: 10.1177/1756287211432777. View

14.

Clark I, Swingler T, Sampieri C, Edwards D . The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol. 2008; 40(6-7):1362-78. DOI: 10.1016/j.biocel.2007.12.006. View

15.

Yoshino Y, Kageshita T, Nakajima M, Funakubo M, Ihn H . Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma. J Dermatol. 2008; 35(4):206-14. DOI: 10.1111/j.1346-8138.2008.00446.x. View

16.

Orimo A, Gupta P, Sgroi D, Arenzana-Seisdedos F, Delaunay T, Naeem R . Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005; 121(3):335-48. DOI: 10.1016/j.cell.2005.02.034. View

17.

Chirco R, Liu X, Jung K, Kim H . Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. 2006; 25(1):99-113. DOI: 10.1007/s10555-006-7893-x. View

18.

Luparello C, Avanzato G, Carella C, Pucci-Minafra I . Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat. 1999; 54(3):235-44. DOI: 10.1023/a:1006121129382. View

19.

Huang M, Narita S, Tsuchiya N, Ma Z, Numakura K, Obara T . Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome. Carcinogenesis. 2011; 32(11):1589-96. DOI: 10.1093/carcin/bgr182. View

20.

Shimoda M, Mellody K, Orimo A . Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol. 2009; 21(1):19-25. PMC: 2828545. DOI: 10.1016/j.semcdb.2009.10.002. View